An increase in anti-HBc prevalence occurred in CAR from 12 months old, peaking at 33.8% between 36 and 48 months old. This increase is observed at later ages in Senegal and Cameroon, 18 and 36 months, respectively, reaching a stable level between 10% and 15%.
The distribution of anti-HBc according to age was also performed among the 406 children with complete vaccination (3 injections reported in the immunization card; Figure 2). Although we observed a similar strong decrease in anti-HBc antibodies after the age of 12 months compared with the overall population, we did not observe an increase in the antibodies among children over 24 months old in this subgroup.
Risk Factors Associated with HBV Exposure
The prevalence of anti-HBc among the children older than 12 months, reflecting HBV exposure, was 16.6%, with a significant difference among the 3 countries [26.9% (128/476) in CAR, 13% (42/323) in Senegal and 8.9% (43/485) in Cameroon; P < 0.001)].
Multivariate analysis results showed that being older than 28 months, living in CAR and in a household without flushing toilets were factors independently associated with an increased risk of HBV exposure, defined as anti-HBc positivity among children older than 12 months (Table 3).
Seroprevalence of HBsAg Positivity
Among the 166 anti-HBc-positive and anti-HBs-negative children, 33 were found positive for HBsAg: 27 in CAR, 5 in Cameroon and 1 in Senegal. Thirty-two children had no immunization card, and an immunization card from 1 boy aged 15 months originated from CAR indicated that he was vaccinated, but not with the HBV vaccine. Only 1 child was between 7 and 12 months of age, 9 (27%) were between 13 and 24 months of age and the remaining 23 children (70%) were older than 24 months. Twenty-three children were born before HBV vaccine introduction in the respective EPIs (2008 in CAR and 2005 in Cameroon) and 8 were born during the year of introduction and thus probably did not receive the vaccine.
The percentage of HBsAg-positive children was significantly higher in CAR compared with Cameroon and Senegal (respectively, 5.1%, 0.7% and 0.2%; P < 0.001). Among the HBsAg-positive children, 22/33 were HBeAg positive [20/27 (74%) in CAR, 1/3 in Cameroon and only 1 child HBsAg positive in Senegal]. Viral load median was 8 log IU/mL with values ranging from 5.2 to 8.2 log IU/mL. Figure 3 shows after a rapid decrease in anti-HBc until the age of 12 months, a parallel evolution between the prevalence of HBsAg and anti-HBc after the age of 18 months and an increase in the 2 markers between 18 and 36 months old, with stabilization after 36 months. In Senegal, while the prevalence of exposed children (anti-HBc-positive) was relatively high (21.4%), only 1 child was HBsAg positive.
Our results show a 19.4% anti-HBc-positive prevalence in children aged 3 months to 6 years old in 5 hospitals in 3 African countries and 16.6% among children older than 12 months. The overall percentage of children anti-HBc positive observed among the children younger than 6 months was particularly high (44.4%), decreasing rapidly and consistently reaching 18.8% between 6 and 12 months old. It is generally accepted that maternal antibodies are detectable until 18 months of age. Here, we show that maternal anti-HBc disappeared earlier, before the age of 12 months, in our population of children born to exposed mothers and that almost 50% of the mothers have been exposed to the virus HBV. This rapid decline of anti-HBc antibodies suggests that many antibodies detected at these ages were of maternal origin, with a time-declining affinity and avidity of passively transmitted antibodies. In the assay procedure, children’s serum samples and recombinant HBcAg are incubated in antibody-coated microwells. If anti-HBc antibodies are present in a specimen, they compete with the antibody coated in the microwells for the recombinant HBcAg. The quantity of tracer that binds to the solid phase via recombinant HBcAg and the consequent enzyme activity are inversely related to the anti-HBc concentration present in the specimen. So, the use of a competitive EIA test to detect passively transmitted antibodies such as anti-HBc in this study is particularly well adapted to differentiate between the passively transmitted low affinity antibodies versus newly synthesized higher affinity antibodies against the core of the HBV. This explains the rapid decline in anti-HBc reactivity observed with the competitive EIA, as previously observed with other antibodies passively transmitted to children in HIV-infected mothers.26
Our results confirm those obtained by Barin et al3 before the administration of HBV vaccine in Senegal in 1981, who reported a similar rapid decline of the anti-HBc antibodies between the ages of 6 and 12 months. After declining during the first 12 months of life, the anti-HBc positivity increased in different ways in the 3 countries. Although the prevalence of anti-HBc increased immediately after 12 months in CAR and continued rising steadily until 72 months, the anti-HBc prevalence increased later in Cameroon (36 months) and Senegal (18 months). The profile observed in CAR, which shows that HBV exposure occurs as early as 12 months, is in accordance with the late introduction of HBV vaccine in the EPI (2008) and is consistent with data reported in South Africa before the integration of the HBV vaccine.28
In Cameroon, HBV exposure occurs among children older than 36 months, a result consistent with integration of the HBV vaccine to the EPI in 2005, when these children were not vaccinated against HBV. The 10% HBV exposure observed after the age of 12 months is consistent with the generally observed 10% nonresponse observed among children vaccinated with HBV vaccine.21,25,27
In contrast to Cameroon, in Senegal, there was a peak of anti-HBc among children between 18 and 36 months old. This increase in anti-HBc among children born after integration of HBV vaccine can be explained by the fact that these children were not protected against HBV infection. This hypothesis is supported by our previously published results from this cohort of patients,21 which showed that a high proportion of Senegalese children vaccinated during the years 2006 and 2007 did not respond to HBV vaccine (43%). This low level of protected children contrasted with 86% HBV vaccine coverage reported by the WHO in Senegal for the same years.30 This lack of response to HBV vaccination could be due to problems with storage conditions in Senegal, or to a quality problem with the vaccine preparation, or it may be related to children’s nutritional status, particularly frequent in this population of Senegalese children. Moreover, there may have been a delay between the time the vaccine was officially introduced in the EPI and when it was actually available in all vaccination centers. Despite the peak of anti-HBc observed between 18 and 36 months, the antibody level was low in Senegal compared with that reported by Barin in 1981 before the introduction of the HBV vaccination.3
When repeating the same analysis globally in all 3 countries among the 406 children vaccinated against HBV with 3 injections according to immunization cards, we confirmed the same decrease in anti-HBc at 12 months old. We did not observe an increase in the anti-HBc after the age of 12 months. The low number of children with an immunization card did not permit a separate analysis by country.
We identified 3 factors that positively correlated with exposure: (1) age, with the older children being the most infected, reflecting the year that HBV vaccine was integrated into the EPI; (2) living in CAR, revealing the positive impact of anti-HBV vaccination in Senegal and Cameroon and (3) non-flushing toilet. Having a flushing toilet in Africa may reflect more than a means of human waste disposal. The hypothesis for HBV contamination in childhood is based on prolonged contact with infected people, by inoculation of HBV into cutaneous scratches, abrasions or other lesions.25 A higher risk among children with low socioeconomic levels may explain a higher risk of HBV transmission. It has been suggested that HBV exposure occurring during the first 4 years of life resulted from mother-children transmission, whereas infection occurring after this age was due to horizontal transmission at home or school.3,14 However, the mode of HBV horizontal transmission is not fully understood.10
HBsAg was found in 33 of 1783 children (1.9%), with different percentages depending on the country. The prevalence of HBsAg-positive children reached 5.1% in CAR, whereas it was only 0.7% in Cameroon and 0.2% in Senegal.
Our results show that all HBsAg are detected only after 6 months of age among the population of children anti-HBc positive and anti-HBs negative, suggesting that the children were infected by horizontal transmission and that immunization at 6 weeks should prevent HBV. However, because of the small number12 of children younger than 6 months in CAR, these results should be confirmed with further studies that involve more children.
The viral load among HBsAg-positive children was high, a result consistent with an immunotolerant stage of HBV. This stage, characterized by a high viral load and HBeAg positivity, displays neither inflammatory activity nor the onset of fibrosis. It occurs among those infected at birth or during early infancy.13
Only children anti-HBc positive and anti-HBs negative were tested for the HBsAg. This lack of systematic HBsAg research may have resulted in an underestimation of HBV infection. Nevertheless, the strong correlation between the presence of anti-HBc and HBsAg during HBV infection confirms the relevance of using anti-HBc detection to highlight any exposure to HBV among these children.
Our results obtained in Cameroon and Senegal between 2009 and 2010, 4 years after the introduction of the HBV vaccine into the EPI, show a decrease in anti-HBc antibodies among children born after the 2005 integration of the HBV vaccine into the EPI in Senegal and Cameroon, suggesting a positive impact on HBV exposure. In addition, the prevalence of HBsAg is lower in Cameroon and Senegal among our population of children compared with the historical data,3,6 suggesting a positive impact on HBV infection. These findings are certainly debatable, because the seromarkers were not measured in a comparable population of hospitalized children before the beginning of vaccination. Besides, because our children were recruited in emergency rooms of pediatric hospitals, the prevalence of anti-HBc and HBsAg positivity that we observed may have been overestimated, even if most reasons for hospitalization were not directly related to hepatitis. Finally, the introduction of the HBV vaccine into the EPI in our 3 countries is certainly too recent to assess its impact on the risks of HBV exposure in noninfected subjects.
This cross-sectional study, conducted without following up on included children, limits our ability to estimate true anti-HBc prevalence but suggest a positive impact of the integration of the HBV vaccine on HBV infection. Long-term follow-up studies have shown the effectiveness of HBV immunization programs on HBV exposure and infection by measuring the anti-HBc and HBsAg.15,17,24 However, because cohort studies are time-consuming and costly, and because the public health significance of anti-HBc measurement is debatable, serological surveys of HBsAg and anti-HBc prevalence should be conducted to evaluate the effectiveness of the HBV vaccine after its integration into the EPI, as recommended by the WHO.31
As soon as children exceed the age of 12 months, it is possible to differentiate between passive transfer of anti-HBc maternal antibodies and antibody responses to HBV exposure. Decrease in anti-HBc antibodies among children born after the 2005 integration of the HBV vaccine into the EPI in Senegal and Cameroon, as well as the low prevalence of HBsAg, suggests a positive impact of HBV vaccination. Immunization coverage and the prevalence of HBV infection observed in our studies are encouraging for health authorities to continue their important work in strengthening vaccination programmes in Africa.
The authors thank all the children and their families for the time and effort they devoted to the study. They are also grateful for the cooperation and support of the field staff, health sector personal and laboratory personnel. They wish to thank Dr. Tamara Giles-Vernick for rereading the manuscript.
1. Abebe A, Nokes DJ, Dejene A, et al. Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control. Epidemiol Infect. 2003;131:757–770
2. André F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine. 2000;18(suppl 1):S20–S22
3. Barin F, Perrin J, Chotard J, et al. Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal. Prog Med Virol. 1981;27:148–162
4. Bile K, Mohamud O, Aden C, et al. The risk for hepatitis A, B, and C at two institutions for children in Somalia with different socioeconomic conditions. Am J Trop Med Hyg. 1992;47:357–364
6. Chiaramonte M, Stroffolini T, Ngatchu T, et al. Hepatitis B virus infection in Cameroon: a seroepidemiological survey in city school children. J Med Virol. 1991;33:95–99
7. Foupouapouognigni Y, Mba SA, Betsem à Betsem E, et al. Hepatitis B and C virus infections in the three Pygmy groups in Cameroon. J Clin Microbiol. 2011;49:737–740
8. Garrigue G, Merlin M, Durand JP, et al. [Prevalence of markers of viral hepatitis B in northern Cameroon]. Bull Soc Pathol Exot Filiales. 1985;78(5 pt 2):883–889
9. Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329–1339
10. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut. 1996;38(suppl 2):S5–S12
11. Komas NP, Bai-Sepou S, Manirakiza A, Leal J, Bere A, Le Faou A. The prevalence of hepatitis B virus markers in a cohort of students in Bangui, Central African Republic. BMC Infect Dis. 2010;10:226
12. Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res. 2007;37(s1):S9–S19
13. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther. 2010;3:25–33
14. Martinson FE, Weigle KA, Royce RA, et al. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol. 1998;147:478–487
15. Mendy M, Peterson I, Hossin S, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One. 2013;8:e58029
16. Meunier DM, Vohito MD, Courrouce AM, et al. [Prevalence of hepatitis B surface antigen and determination of its subtypes in the Central African Republic]. Bull Soc Pathol Exot Filiales. 1984;77:249–254
17. Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012;57:730–735
18. Pawlotsky JM, Bélec L, Grésenguet G, et al. High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. J Med Virol. 1995;46:269–272
19. Pellizzer G, Blè C, Zamperetti N, et al. Serological survey of hepatitis B infection in Tanzania. Public Health. 1994;108:427–431
20. Prozesky OW, Szmuness W, Stevens CE, et al. Baseline epidemiological studies for a hepatitis B vaccine trial in Kangwane. S Afr Med J. 1983;64:891–893
21. Rey-Cuille MA, Seck A, Njouom R, et al. Low immune response to hepatitis B vaccine among children in Dakar, Senegal. PLoS One. 2012;7:30
22. Roingeard P, Diouf A, Sankale JL, et al. Perinatal transmission of hepatitis B virus in Senegal, west Africa. Viral Immunol. 1993;6:65–73
23. Sall Diallo A, Sarr M, Fall Y, Diagne C, Kane MO. [Hepatitis B infection in infantile population of Senegal]. Dakar Med. 2004;49:136–142
24. Shen L, Wang F, Wang F, et al. Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China. Vaccine. 2012;30:6623–6627
25. Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–125
26. Simon F, Rahimy C, Krivine A, et al. Antibody avidity measurement and immune complex dissociation for serological diagnosis of vertically acquired HIV-1 infection. J Acquir Immune Defic Syndr. 1993;6:201–207
27. van der Sande MA, Waight P, Mendy M, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis. 2006;193:1528–1535
28. Vardas E, Mathai M, Blaauw D, et al. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol. 1999;58:111–115
29. Vray M, Debonne JM, Sire JM, et al. Molecular epidemiology of hepatitis B virus in Dakar, Senegal. J Med Virol. 2006;78:329–334
HBV markers; HBV exposure; HBV vaccine; childhood© 2013 by Lippincott Williams & Wilkins, Inc.